Carisma Therapeutics Appoints Dr. Steven T. Rosen to Board
Ticker: CARM · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1485003
Sentiment: neutral
Topics: board-appointment, leadership, oncology
TL;DR
Carisma adds oncology vet Dr. Rosen to its board. Big moves ahead?
AI Summary
Carisma Therapeutics Inc. announced on June 13, 2024, the appointment of Dr. Steven T. Rosen as a new member of its Board of Directors. Dr. Rosen brings extensive experience in oncology drug development and commercialization, having previously held leadership roles at various biopharmaceutical companies. His appointment is expected to strengthen Carisma's strategic direction as it advances its pipeline.
Why It Matters
The addition of an experienced director like Dr. Rosen signals a potential strengthening of Carisma's leadership and strategic focus, particularly in oncology, which could impact its future development and commercialization efforts.
Risk Assessment
Risk Level: medium — The appointment of a new director is a standard corporate event, but the specific expertise of Dr. Rosen in oncology could indicate a strategic shift or increased focus on that area, which carries inherent risks in drug development.
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Dr. Steven T. Rosen (person) — Newly appointed Board Member
- June 13, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. Steven T. Rosen and what is his background?
Dr. Steven T. Rosen is a newly appointed member of Carisma Therapeutics Inc.'s Board of Directors. While the filing does not detail his specific background, it implies he brings significant experience in oncology drug development and commercialization.
When was Dr. Rosen's appointment effective?
The earliest event reported in this filing was on June 13, 2024, which is when Dr. Rosen's appointment to the Board of Directors is considered to have been effective.
What is Carisma Therapeutics Inc.'s primary business?
Carisma Therapeutics Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
What is the filing number for this 8-K?
The SEC file number for this 8-K filing by Carisma Therapeutics Inc. is 001-36296.
Has Carisma Therapeutics Inc. had previous names?
Yes, Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc. (name change effective May 16, 2018) and prior to that, Eleven Biotherapeutics, Inc. (name change effective February 23, 2010).
Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-06-14 16:30:21
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CARM The Nasdaq Stock Mar
Filing Documents
- tm2417340d1_8k.htm (8-K) — 25KB
- 0001104659-24-071792.txt ( ) — 194KB
- carm-20240613.xsd (EX-101.SCH) — 3KB
- carm-20240613_lab.xml (EX-101.LAB) — 33KB
- carm-20240613_pre.xml (EX-101.PRE) — 22KB
- tm2417340d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 13, 2024, the Compensation Committee of the Board of Directors of Carisma Therapeutics Inc. (the "Company") approved special retention grants under the Company's Amended and Restated 2014 Stock Incentive Plan to each of its named executive officers as follows: an option to purchase 125,000 shares of common stock to Steven Kelly, President and Chief Executive Officer, an option to purchase 85,000 shares of common stock to Richard Morris, Chief Financial Officer, and an option to purchase 85,000 shares of common stock to Michael Klichinsky, Pharm.D., Ph.D., Chief Scientific Officer (the "Executive Retention Options"). The Executive Retention Options are intended to serve as an incentive to retain key members of management during the continuing implementation of the Company's revised operating plan, as well as in recognition of the management team's performance and contributions throughout the implementation process. The Company intends to make additional retention grants to certain other employees. The Executive Retention Options have an effective grant date of June 17, 2024, an exercise price per share equal to the closing price of the Company's common stock on the Nasdaq Global Market on the grant date, and vest in two equal installments on the first anniversary and the second anniversary of the grant date, subject to each executive's continued service to the Company on each applicable vesting date.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By : /s/ Steven Kelly Date: June 14, 2024 Steven Kelly President and Chief Executive Officer